New Cancer Drugs Show Promising Results in Improving Survival and Reducing Disease Progression.
TL;DR
ImmunoGen's ELAHERE has demonstrated a 35% reduction in the risk of disease progression or death compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC), according to results from the Phase 3 confirmatory MIRASOL trial. ELAHERE is the first treatment to show an overall survival benefit in this patient population. The data further support the potential of ELAHERE to become the new standard of care for patients with FRα-positive platinum-resistant ovarian cancer.
- ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer Yahoo Finance
- Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma Medical Xpress
- Mirvetuximab Soravtansine Improves Survival in Patients With Recurrent Ovarian Cancer The ASCO Post
- New Ovarian Cancer Drug Extends Survival in Resistant Disease Medpage Today
- Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC Cancer Network
Want the full story? Read the original reporting
Read on Yahoo Finance